Rapamycin & Metformin for Longevity: The Evidence

Two drugs, one honest gap

Rapamycin and metformin are the two repurposed drugs most discussed as potential geroprotectors. Both have a compelling preclinical story. Both share the same limitation: no completed human longevity RCT proves either one extends healthy lifespan in people. The animal data is real; the human proof is not here yet. For the full toolkit, see longevity medicine: what's proven vs hyped.

Rapamycin: the strongest animal data in the field

If you rank interventions by animal lifespan evidence, rapamycin sits at the top. mTOR inhibition is the most reproducible pharmacologic lifespan extender across model organisms, validated in the rigorous NIA Interventions Testing Program. But an authoritative review is blunt about the ceiling: no rapalog has been shown to extend human lifespan or healthspan, and the human evidence base remains early¹. We unpack the mechanism, the mouse data, and the immunosuppressive and metabolic risks in depth in rapamycin for longevity: hype vs evidence.

What the human pilot actually showed

The PEARL trial is among the first human longevity-oriented RCTs of rapamycin — a decentralized, placebo-controlled study of low-dose oral rapamycin over one year in healthy adults. It found acceptable safety and a few modest subgroup signals, such as improvements in lean mass and pain in women². What it did not find is decisive: no demonstrated effect on aging biomarkers or lifespan. The trial was small, short, and leaned heavily on self-reported measures². It is a safety-and-feasibility pilot, not proof of anti-aging benefit — and it actually missed its primary endpoint of visceral-fat reduction, which we unpack in what the PEARL trial actually showed about rapamycin.

Metformin: observational hope, no completed RCT

Metformin's longevity case is mechanistic and observational. A review maps the drug's actions onto the recognized hallmarks of aging, summarizing a largely preclinical and observational basis for geroprotection³. The most-cited human signal comes from a large observational study in which metformin-treated people with type 2 diabetes had survival comparable to — even slightly better than — matched non-diabetic controls⁴.

That finding is striking but hypothesis-generating only. It is observational, confounded, and was conducted in people with diabetes; it is not evidence that metformin extends healthy lifespan in people without diabetes. People prescribed metformin differ from those who aren't in countless ways an observational study can't fully untangle, and a result in diabetics says little about geroprotection in healthy adults. The mechanistic story — metformin nudging several hallmarks of aging — is genuinely interesting, but "plausible mechanism plus suggestive association" is precisely the evidence tier this site grades down, not up.

TAME: the trial designed because the proof is missing

The clearest tell that metformin's anti-aging benefit is unproven is that the field built an entire trial to test it. The TAME (Targeting Aging with Metformin) rationale paper explicitly argues that a definitive RCT is still needed⁵. TAME is a design-and-rationale case, not a results paper. You do not propose a landmark trial to confirm something already proven. For the full metformin-specific breakdown — including the randomized finding that it can blunt exercise adaptations in older adults — see metformin for longevity: the TAME trial evidence.

Reading the two honestly

• •Rapamycin: best-in-class animal lifespan data; human evidence limited to a one-year safety pilot (PEARL) with no demonstrated aging-biomarker or lifespan effect. Grade: strong animal, absent human-longevity RCT.
• •Metformin: mechanistically plausible and observationally suggestive in diabetics; no completed RCT shows healthy-lifespan extension in non-diabetics. Grade: observational/mechanistic, awaiting TAME-type proof.

Neither belongs in the same evidence tier as interventions with hard human outcomes.

[[figure:1]] The methodology for proving healthspan benefit in humans is still being built — a reminder that the whole field, including these two front-runners, sits largely upstream of definitive trials. It is worth saying plainly that "front-runner" here means best-supported by animal and mechanistic work, not validated in people. The gap between a mouse lifespan curve and a human healthspan benefit has swallowed many promising compounds before, and rapamycin and metformin have not yet crossed it.

What this means if a clinic offers them

Some longevity clinics prescribe off-label rapamycin or metformin. That is not inherently unreasonable, but the honest framing matters: you would be an early adopter of an intervention with strong animal data and unsettled human longevity evidence, not a recipient of a proven anti-aging therapy. A trustworthy provider will say exactly that. For how to vet providers, see are longevity clinics worth it?, and for NAD+ and peptide claims, do NAD+ and peptides actually extend lifespan?.